Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Total Non-Current Liabilities (2020 - 2021)

Protagonist Therapeutics (PTGX) has disclosed Total Non-Current Liabilities for 2 consecutive years, with $43.4 million as the latest value for Q3 2021.

  • Quarterly Total Non-Current Liabilities fell 8.76% to $43.4 million in Q3 2021 from the year-ago period, while the trailing twelve-month figure was $43.4 million through Sep 2021, down 8.76% year-over-year, with the annual reading at $44.7 million for FY2020, N/A changed from the prior year.
  • Total Non-Current Liabilities hit $43.4 million in Q3 2021 for Protagonist Therapeutics, down from $46.7 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $57.4 million in Q2 2020 to a low of $38.6 million in Q1 2021.